These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

424 related items for PubMed ID: 16640170

  • 21. Long-acting calcium antagonists in patients with coronary artery disease: a meta-analysis.
    Bangalore S, Parkar S, Messerli FH.
    Am J Med; 2009 Apr; 122(4):356-65. PubMed ID: 19332231
    [Abstract] [Full Text] [Related]

  • 22. Nimodipine in subcortical vascular dementia trial.
    Rossi R, Inzitari D, Pantoni L, del Ser T, Erkinjuntti T, Wallin A, Bianchi C, Badenas JM, Beneke M.
    Alzheimer Dis Assoc Disord; 1999 Apr; 13 Suppl 3():S159-65. PubMed ID: 10609696
    [Abstract] [Full Text] [Related]

  • 23. Hypertension and the brain. The National High Blood Pressure Education Program.
    Phillips SJ, Whisnant JP.
    Arch Intern Med; 1992 May; 152(5):938-45. PubMed ID: 1580719
    [Abstract] [Full Text] [Related]

  • 24. [Vascular and neuronal mechanisms of calcium antagonists. Significance in neurological therapy].
    Govoni S, Trabucchi M, Battaini F, Magnoni MS, Paoletti R.
    Minerva Med; 1986 Jun 08; 77(24):1053-8. PubMed ID: 3725133
    [Abstract] [Full Text] [Related]

  • 25. Antihypertensive treatment and stroke prevention: are angiotensin receptor blockers superior to other antihypertensive agents?
    Armario P, de la Sierra A.
    Ther Adv Cardiovasc Dis; 2009 Jun 08; 3(3):197-204. PubMed ID: 19443514
    [Abstract] [Full Text] [Related]

  • 26. From pharmacological promises to controlled clinical trials to meta-analysis and back: the case of nimodipine in cerebrovascular disorders.
    Di Mascio R, Marchioli R, Tognoni G.
    Clin Trials Metaanal; 1994 Apr 08; 29(1):57-79. PubMed ID: 10150186
    [Abstract] [Full Text] [Related]

  • 27. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors.
    Fournier A, Oprisiu-Fournier R, Serot JM, Godefroy O, Achard JM, Faure S, Mazouz H, Temmar M, Albu A, Bordet R, Hanon O, Gueyffier F, Wang J, Black S, Sato N.
    Expert Rev Neurother; 2009 Sep 08; 9(9):1413-31. PubMed ID: 19769454
    [Abstract] [Full Text] [Related]

  • 28. Prevention of neuronal damage by calcium channel blockers with antioxidative effects after transient focal ischemia in rats.
    Lukic-Panin V, Kamiya T, Zhang H, Hayashi T, Tsuchiya A, Sehara Y, Deguchi K, Yamashita T, Abe K.
    Brain Res; 2007 Oct 24; 1176():143-50. PubMed ID: 17904110
    [Abstract] [Full Text] [Related]

  • 29. [Hypertension and the brain].
    Christensen H, Strandgaard S.
    Ugeskr Laeger; 2009 Jun 08; 171(24):2025-8. PubMed ID: 19523368
    [Abstract] [Full Text] [Related]

  • 30. Calcium channel blockers and nephroprotection.
    Ungar A, Di Serio C, Lambertucci L, Monami M, Masotti G.
    Aging Clin Exp Res; 2005 Aug 08; 17(4 Suppl):31-9. PubMed ID: 16640171
    [Abstract] [Full Text] [Related]

  • 31. Progress in cardiovascular diseases: cognitive function in essential hypertension.
    Birkenhäger WH, Staessen JA.
    Prog Cardiovasc Dis; 2006 Aug 08; 49(1):1-10. PubMed ID: 16867845
    [Abstract] [Full Text] [Related]

  • 32. Effects of calcium channel and renin-angiotensin system blockade on intravascular and neurohormonal mechanisms of hypertensive vascular disease.
    Mizuno Y, Jacob RF, Mason RP.
    Am J Hypertens; 2008 Oct 08; 21(10):1076-85. PubMed ID: 18756260
    [Abstract] [Full Text] [Related]

  • 33. Antihypertensive therapy and cerebrovascular protection.
    Volpe M, Tocci G.
    Curr Opin Nephrol Hypertens; 2006 Sep 08; 15(5):498-504. PubMed ID: 16914962
    [Abstract] [Full Text] [Related]

  • 34. Use of injectable nicardipine for neurovascular indications.
    Reddy P, Yeh YC.
    Pharmacotherapy; 2009 Apr 08; 29(4):398-409. PubMed ID: 19323619
    [Abstract] [Full Text] [Related]

  • 35. [Risk factors and mechanisms of post-stroke dementia].
    Pasquier F, Hénon H, Leys D.
    Rev Neurol (Paris); 1999 Apr 08; 155(9):749-53. PubMed ID: 10528361
    [Abstract] [Full Text] [Related]

  • 36. Actions of calcium channel blockers on vascular proteoglycan synthesis: relationship to atherosclerosis.
    Survase S, Ivey ME, Nigro J, Osman N, Little PJ.
    Vasc Health Risk Manag; 2005 Apr 08; 1(3):199-208. PubMed ID: 17319105
    [Abstract] [Full Text] [Related]

  • 37. Antihypertensive treatment and stroke prevention in patients with and without chronic kidney disease: a review of controlled trials.
    Segall L, Oprisiu R, Fournier A, Covic A.
    J Nephrol; 2008 Apr 08; 21(3):374-83. PubMed ID: 18587726
    [Abstract] [Full Text] [Related]

  • 38. Anesthetic considerations of selective intra-arterial nicardipine injection for intracranial vasospasm: a case series.
    Avitsian R, Fiorella D, Soliman MM, Mascha E.
    J Neurosurg Anesthesiol; 2007 Apr 08; 19(2):125-9. PubMed ID: 17413999
    [Abstract] [Full Text] [Related]

  • 39. Ca2+ channel subtypes and pharmacology in the kidney.
    Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T.
    Circ Res; 2007 Feb 16; 100(3):342-53. PubMed ID: 17307972
    [Abstract] [Full Text] [Related]

  • 40. Managing hypertension using combination therapy.
    Frank J.
    Am Fam Physician; 2008 May 01; 77(9):1279-86. PubMed ID: 18540493
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.